Dosiomic predictors of biochemical failure in patients with localized prostate cancer treated with Iodine-125 low-dose-rate brachytherapy
Abstract Background This study aimed to identify dosiomic features that have a significant impact on biochemical failure (BCF) following low-dose rate (LDR) brachytherapy treatment using Iodine-125 seeds for prostate cancer and to provide insights into LDR brachytherapy treatment efficacy using a do...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Radiation Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13014-025-02619-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850181555724484608 |
|---|---|
| author | Masahiro Nakano Shizuo Kaji Shogo Kawakami Hideyasu Tsumura Toshikazu Imae Yuichi Tanaka Kyohei Fujii Takuro Kainuma Ryosuke Yamazaki Ayaka Uchida Hijiri Kaneko Mako Fujino Chizu Hata Yu Murakami Masatoshi Hashimoto Hiromichi Ishiyama |
| author_facet | Masahiro Nakano Shizuo Kaji Shogo Kawakami Hideyasu Tsumura Toshikazu Imae Yuichi Tanaka Kyohei Fujii Takuro Kainuma Ryosuke Yamazaki Ayaka Uchida Hijiri Kaneko Mako Fujino Chizu Hata Yu Murakami Masatoshi Hashimoto Hiromichi Ishiyama |
| author_sort | Masahiro Nakano |
| collection | DOAJ |
| description | Abstract Background This study aimed to identify dosiomic features that have a significant impact on biochemical failure (BCF) following low-dose rate (LDR) brachytherapy treatment using Iodine-125 seeds for prostate cancer and to provide insights into LDR brachytherapy treatment efficacy using a dosiomic approach. Methods Between January 2005 and February 2015, 1,205 patients with localized prostate cancer underwent Iodine-125 seed implantation without combined external irradiation. A total of 96 patients were selected for this study, including 48 with BCF and 48 without BCF. The patients were divided into two cohorts: derivation and validation. Dose distribution images (DDs) were calculated from computed tomography (CT) images taken one month after implantation. A total of 1,130 dosiomic features, including shape-and-size, histogram, and texture features, were extracted from these DDs, their wavelet-transformed images, and Laplacian-of-Gaussian (LoG)-filtered images. The features obtained were categorized into three groups: shape-and-size (S), histogram (H), and texture (T). The Boruta algorithm was used to eliminate less important features. Two analyses were performed: Analysis A performed a multivariate logistic regression analysis using data from the validation cohort to identify significant features. Analysis B generated logistic regression models using derivation cohort data. The accuracy of BCF prediction was assessed using the validation cohort, with performance measured using the area under the receiver operating characteristic curve (AUC). Results After the feature reduction process, two, two, and four features remained in the S, H, and T feature groups, respectively. In analysis A, the multivariate logistic regression identified four dominant features, two from each of the S and T groups. In analysis B, the AUC of the logistic regression prediction models using S, H, and all four features were 0.81, 0.77, and 0.86, respectively. Conclusions Four significant dosiomic features were identified. Notably, three features—elongation, Maximum2DDiameterRow, and wavelet-HHL_Skewness—strongly distinguished patients with favorable prognoses from others. These findings suggest that dosiomic features from postimplant CT and dose distribution may serve as effective factors for evaluating LDR brachytherapy outcomes in patients with prostate cancer. |
| format | Article |
| id | doaj-art-4db561228a054cd09f0fc8b18c633c94 |
| institution | OA Journals |
| issn | 1748-717X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj-art-4db561228a054cd09f0fc8b18c633c942025-08-20T02:17:52ZengBMCRadiation Oncology1748-717X2025-04-0120111110.1186/s13014-025-02619-6Dosiomic predictors of biochemical failure in patients with localized prostate cancer treated with Iodine-125 low-dose-rate brachytherapyMasahiro Nakano0Shizuo Kaji1Shogo Kawakami2Hideyasu Tsumura3Toshikazu Imae4Yuichi Tanaka5Kyohei Fujii6Takuro Kainuma7Ryosuke Yamazaki8Ayaka Uchida9Hijiri Kaneko10Mako Fujino11Chizu Hata12Yu Murakami13Masatoshi Hashimoto14Hiromichi Ishiyama15Department of Radiation Oncology, Kitasato University School of MedicineInstitute of Mathematics for Industry, Kyushu UniversityDepartment of Radiation Oncology, Kitasato University School of MedicineDepartment of Urology, Kitasato University School of MedicineDepartment of Radiology, The University of Tokyo HospitalDepartment of Radiology, Kitasato University HospitalDepartment of Radiology, Kitasato University HospitalDepartment of Radiation Oncology, Kitasato University School of MedicineDepartment of Radiation Oncology, Kitasato University School of MedicineDepartment of Radiation Oncology, Kitasato University School of MedicineDepartment of Radiation Oncology, Kitasato University School of MedicineDepartment of Radiation Oncology, Kitasato University School of MedicineDepartment of Radiology, Kitasato University HospitalDepartment of Physics, Cancer Institute, Japanese Foundation for Cancer ResearchDepartment of Medical Engineering and Technology, Kitasato University School of Allied Health SciencesDepartment of Radiation Oncology, Kitasato University School of MedicineAbstract Background This study aimed to identify dosiomic features that have a significant impact on biochemical failure (BCF) following low-dose rate (LDR) brachytherapy treatment using Iodine-125 seeds for prostate cancer and to provide insights into LDR brachytherapy treatment efficacy using a dosiomic approach. Methods Between January 2005 and February 2015, 1,205 patients with localized prostate cancer underwent Iodine-125 seed implantation without combined external irradiation. A total of 96 patients were selected for this study, including 48 with BCF and 48 without BCF. The patients were divided into two cohorts: derivation and validation. Dose distribution images (DDs) were calculated from computed tomography (CT) images taken one month after implantation. A total of 1,130 dosiomic features, including shape-and-size, histogram, and texture features, were extracted from these DDs, their wavelet-transformed images, and Laplacian-of-Gaussian (LoG)-filtered images. The features obtained were categorized into three groups: shape-and-size (S), histogram (H), and texture (T). The Boruta algorithm was used to eliminate less important features. Two analyses were performed: Analysis A performed a multivariate logistic regression analysis using data from the validation cohort to identify significant features. Analysis B generated logistic regression models using derivation cohort data. The accuracy of BCF prediction was assessed using the validation cohort, with performance measured using the area under the receiver operating characteristic curve (AUC). Results After the feature reduction process, two, two, and four features remained in the S, H, and T feature groups, respectively. In analysis A, the multivariate logistic regression identified four dominant features, two from each of the S and T groups. In analysis B, the AUC of the logistic regression prediction models using S, H, and all four features were 0.81, 0.77, and 0.86, respectively. Conclusions Four significant dosiomic features were identified. Notably, three features—elongation, Maximum2DDiameterRow, and wavelet-HHL_Skewness—strongly distinguished patients with favorable prognoses from others. These findings suggest that dosiomic features from postimplant CT and dose distribution may serve as effective factors for evaluating LDR brachytherapy outcomes in patients with prostate cancer.https://doi.org/10.1186/s13014-025-02619-6Prostate cancerLow-dose-rate brachytherapyBiochemical failureDosiomic features |
| spellingShingle | Masahiro Nakano Shizuo Kaji Shogo Kawakami Hideyasu Tsumura Toshikazu Imae Yuichi Tanaka Kyohei Fujii Takuro Kainuma Ryosuke Yamazaki Ayaka Uchida Hijiri Kaneko Mako Fujino Chizu Hata Yu Murakami Masatoshi Hashimoto Hiromichi Ishiyama Dosiomic predictors of biochemical failure in patients with localized prostate cancer treated with Iodine-125 low-dose-rate brachytherapy Radiation Oncology Prostate cancer Low-dose-rate brachytherapy Biochemical failure Dosiomic features |
| title | Dosiomic predictors of biochemical failure in patients with localized prostate cancer treated with Iodine-125 low-dose-rate brachytherapy |
| title_full | Dosiomic predictors of biochemical failure in patients with localized prostate cancer treated with Iodine-125 low-dose-rate brachytherapy |
| title_fullStr | Dosiomic predictors of biochemical failure in patients with localized prostate cancer treated with Iodine-125 low-dose-rate brachytherapy |
| title_full_unstemmed | Dosiomic predictors of biochemical failure in patients with localized prostate cancer treated with Iodine-125 low-dose-rate brachytherapy |
| title_short | Dosiomic predictors of biochemical failure in patients with localized prostate cancer treated with Iodine-125 low-dose-rate brachytherapy |
| title_sort | dosiomic predictors of biochemical failure in patients with localized prostate cancer treated with iodine 125 low dose rate brachytherapy |
| topic | Prostate cancer Low-dose-rate brachytherapy Biochemical failure Dosiomic features |
| url | https://doi.org/10.1186/s13014-025-02619-6 |
| work_keys_str_mv | AT masahironakano dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT shizuokaji dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT shogokawakami dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT hideyasutsumura dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT toshikazuimae dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT yuichitanaka dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT kyoheifujii dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT takurokainuma dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT ryosukeyamazaki dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT ayakauchida dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT hijirikaneko dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT makofujino dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT chizuhata dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT yumurakami dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT masatoshihashimoto dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy AT hiromichiishiyama dosiomicpredictorsofbiochemicalfailureinpatientswithlocalizedprostatecancertreatedwithiodine125lowdoseratebrachytherapy |